A nti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets

作者：Moschos Marilita M^*; Moustafa Giannis A; Papakonstantinou Vasiliki D; Tsatsos Michael; Laios Konstantinos; Antonopoulou Smaragdi

来源：Drug Design, Development and Therapy, 2017, 11: 1267-1272.

DOI：10.2147/DDDT.S131582

• glaucoma
• eye
• platelet
• aggregation
• PAF
• TRAP

Purpose: Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with the possibility of establishing it as an additional mechanism of anti-glaucomatous action.
Materials and methods: The anti-aggregating effects of a series of anti-glaucomatous eye drops were determined on human platelets in the platelet aggregation model, using four known aggregating factors (platelet activating factor [PAF], adenosine diphosphate [ADP], thrombin receptor-activating peptide [TRAP], and arachidonic acid [AA]).
Results: Almost all of the tested samples inhibited platelet aggregation induced by PAF, ADP, TRAP, and AA, except for Alphagan, which did not demonstrate inhibition of ADP-and TRAP-induced aggregation at a wide range of concentrations. Trusopt, Betoptic, and Azarga eye drops were the most potent inhibitors of all four aggregating factors, while Alphagan was the least potent (P<0.05).
Conclusion: This study shows that anti-glaucomatous eye drops possess anti-platelet effects, and this was shown for the first time by experimenting on human platelets.

• 出版日期2017